Abbott Gains FDA Nod for Dual-Energy TactiFlex Duo Ablation Catheter
Event summary
- Abbott received FDA approval for its TactiFlex Duo Ablation Catheter on September 8, 2026.
- The device combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter.
- Approval was based on favorable safety and effectiveness data from the FlexPulse IDE study.
- This is Abbott's fifth major electrophysiology approval in just over a year.
The big picture
Abbott's FDA approval for the TactiFlex Duo Ablation Catheter strengthens its position in the cardiac ablation market, particularly in treating complex atrial fibrillation cases. The device's dual-energy capability and integration with Abbott's EnSite X EP System provide physicians with greater precision and flexibility. This approval follows a series of regulatory wins for Abbott, underscoring its strategy to build a comprehensive electrophysiology portfolio. The company is well-positioned to support physicians at every stage of patient care, from diagnosis to advanced treatments for complex arrhythmias.
What we're watching
- Market Adoption
- The pace at which TactiFlex Duo gains adoption among electrophysiologists.
- Competitive Response
- How competitors like Medtronic and Boston Scientific react to Abbott's expanded PFA portfolio.
- Regulatory Expansion
- Whether Abbott can secure additional global approvals for its electrophysiology portfolio.